Kyverna Therapeutics, Inc. (KYTX) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Kyverna Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Valuation | |||||
| P/E Ratio | -2.58x | -1.12x | -334.77x | -26.79x | -29.38x |
| P/B Ratio | 1.79x | 0.54x | 410.94x | 16.58x | -16.74x |
| P/S Ratio | 0.00x | 0.00x | 0.00x | 110.19x | 136.87x |
| Profitability | |||||
| Gross Margin | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | -418.3% | -465.8% |
| Net Margin | 0.0% | 0.0% | 0.0% | -411.3% | -465.9% |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | -395.4% | -455.5% |
| Liquidity | |||||
| Current Ratio | 7.75x | 8.61x | 3.05x | 4.45x | 4.84x |
| Quick Ratio | 7.75x | 8.61x | 3.05x | 4.45x | 4.84x |
| Leverage | |||||
| Debt/Equity | 0.12x | 0.03x | 0.18x | 0.23x | -0.12x |
YoY = year-over-year change. Source: FMP..